Morning Screen News: It is reported that on July 1, 2022, Biotech Co., Ltd. released the first multi-functional Oligo synthesizer SynStar21. This synthesizer has a variety of synthesis functions and can meet the needs of RNA, DNA, DNA/RNA modification and DNA/RNA chimeric Oligo s

Early Screening Network News: It is reported that on July 1, 2022, Berco Biotechnology Co., Ltd. released the first multi-functional Oligo synthesizer SynStar21. This synthesizer has a variety of synthesis functions, which can meet the needs of RNA, DNA, DNA/RNA modification, and DNA/RNA chimeric Oligo synthesis. It has the advantages of high synthesis accuracy, economy, and simple operation.

Figure 1 The multifunctional Oligo synthesizer independently developed by Biotech - SynStar21

The SynStar21 multifunctional Oligo synthesizer was independently developed by Biotech's R&D team after five years of hard work, based on the previous generation of long-chain DNA synthesizers. Deeply optimized hardware and software systems can meet different synthesis needs from scientific experiments to drug development. The SynStar21 synthesizer provides nmol~μmol synthesis specifications. can carry out parallel synthesis of high-quality DNA and RNA oligo synthesis of different types, lengths and modifications. can reach a length of 120nt DNA and 100nt RNA to meet the application needs of different fields.

SynStar21 multifunctional Oligo synthesizer is designed and developed for professional nucleic acid synthesis institutions. In addition to being easy to operate and easy to learn, its software has a friendly interactive interface. It can import pre-designed nucleic acid sequences at one time, or manually enter and modify them. Technicians can master all operations within minutes. At the same time, the work interface can display multiple parameters including: current running time, remaining time, synthesis progress and status, etc., to facilitate the operator to grasp the work progress. After half a year of actual operation and fatigue testing, has fully met the needs of actual work.

Figure 2 SynStar21 multifunctional Oligo synthesizer human-computer interaction interface and high-quality RNA produced by SynStar21 Oligo

According to the Allied Market Research market research report, the global market size of Oligo synthesis in 2020 was US$5.2 billion, and will reach US$26 billion by 2030 . In recent years, great progress has been made in the research and development of nucleic acid drugs. Up to now, FDA has approved more than ten oligonucleotide drugs, including a variety of synthetically modified RNA or DNA, such as antisense oligonucleotide (antisense oligonucleotide (ASO), small interfering RNA (siRNA) and nucleic acid aptamer (aptamer), etc.

At the same time, traditional short-chain DNA Oligo (20-60nt) is an important component of gene sequencing and qPCR platform gene detection , and is widely used in pathogen detection, forensic identification, genetic disease diagnosis, tumor companion diagnosis and other fields. For example, the new coronavirus nucleic acid detection reagents that everyone is familiar with include fluorescently modified and non-modified short-chain DNA Oligo.

The liquid-phase gene chip (Gene Panel) composed of long-chain biotin-modified DNA Oligo (120nt probe) is usually used in conjunction with high-throughput gene sequencing. It is a gene-targeted detection technology that is used in pathogen detection and genetics. It is widely used in medical and health fields such as disease diagnosis, tumor companion diagnosis, and chronic disease risk assessment. It also has broad application prospects in animal and plant molecular breeding and other aspects.

Relying on the high-quality nucleic acid platform, Biotech has developed the liquid phase gene chip (Gene Panel) capture technology TargetCap®. has provided more than 300 Gene Panel models to more than 100 medical testing institutions and scientific research institutions, and has been awarded the "European Heart" Journal", "Nature" and other top academic magazines.

Figure 3 Display of scientific research results of users of Berco liquid phase gene chip technology

my country has always been a major user of various types of Oligo, and has become a major country in synthesizing Oligo in the past 20 years. However, in the field of upstream Oligo synthesis equipment, it has always been restricted by major international manufacturers. . The SynStar21 multifunctional Oligo synthesizer released this time is the culmination of many years of technology research and development in the nucleic acid field by Biotech. It is also a major breakthrough in domestic nucleic acid synthesis technology in the field of software and hardware. It fills the gap in this field in my country. The advancement from a country that uses synthetic nucleic acids to a country that produces synthetic nucleic acids, and then to a country that produces upstream equipment for nucleic acid synthesis has laid a solid foundation.

Berco Biotechnology Co., Ltd. is a leading company in synthetic biology underlying technology, dedicated to the development and transformation of new technologies for synthetic biology and genomics. In the future, relying on the underlying technology of synthetic biology, BioBio will actively expand into fields such as gene therapy, nucleic acid drugs, DNA storage, DNA materials science, and molecular breeding, in order to achieve the corporate mission of "strive for excellence and innovation for a better life for mankind". effort.